Stock Report

Download full stock data and analysis for free Last Updated: 04-Nov-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Abbott Laboratories (ABT) Key Ratios

Stock Card factsheet share-fund-plan-icon

$109.40

up-down-arrow $-0.76 (-0.69%)

As on 03-Nov-2026 16:14EST

Market cap

info icon

$180,946 Mln

Revenue (TTM)

info icon

$48,229 Mln

P/E Ratio

info icon

38.9

P/B Ratio

info icon

3.5

Div. Yield

info icon

2.5 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 3.34 14.46 10.00 6.47 2.65
EBIT -- -- -34.24 -5.79 -8.13
Net Profit -0.86 -44.04 -66.37 -3.07 -9.90
EPS -0.58 -43.68 -66.31 -2.95 -7.81
Book Value -- -- 9.31 12.57 10.24
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-25Dec-24
EBIT-Margin info 18.7919.2311.8219.8718.15
Net Margin info --16.009.75----
Return on equity info 19.7819.8218.0613.0731.07
Return on Capital info 14.4513.82--10.0322.83
Return on Assets info 10.9510.349.527.7617.33
Debt to Equity (x) info ------0.290.32

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abbott Laboratories (ABT)
--
10.03
22.83
10.49
12.64
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

18.06

Higher than Peers by 12.88

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abbott Laboratories (ABT)
18.06
13.07
31.07
15.20
19.13
Peer Median
5.18
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

9.52

Higher than Peers by 6.88

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abbott Laboratories (ABT)
9.52
7.76
17.33
7.75
9.27
Peer Median
2.63
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

11.82

Higher than Peers by 2.90

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abbott Laboratories (ABT)
11.82
19.87
18.15
18.35
19.75
Peer Median
8.92
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

9.75

Higher than Peers by 4.44

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abbott Laboratories (ABT)
9.75
14.72
31.95
14.27
15.70
Peer Median
5.31
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

--

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abbott Laboratories (ABT)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

10.00

Higher than Peers by 0.74

Year on year growth in net sales

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abbott Laboratories (ABT)
10.00
0.06
0.05
-0.08
0.01
Peer Median
9.26
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

-34.24

Lower than Peers by 47.61

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abbott Laboratories (ABT)
-34.24
15.64
3.45
-14.60
--
Peer Median
13.37
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

-66.37

Lower than Peers by 82.13

Year on year growth in profit after tax

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abbott Laboratories (ABT)
-66.37
-51.32
134.18
-17.45
-1.95
Peer Median
15.77
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

-66.31

Lower than Peers by 89.36

Year on year growth in earnings per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abbott Laboratories (ABT)
-66.31
-0.51
1.34
-0.17
0.00
Peer Median
23.05
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abbott Laboratories (ABT)
--
0.29
0.32
0.41
0.49
Peer Median
0.36
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abbott Laboratories (ABT)
--
0.06
0.04
0.03
0.07
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

--

--

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abbott Laboratories (ABT)
--
1.58
1.67
1.64
1.63
Peer Median
2.87
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

--

--

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abbott Laboratories (ABT)
--
1.18
1.23
1.16
1.23
Peer Median
2.10
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

8.37

Higher than Peers by 3.14

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abbott Laboratories (ABT)
8.37
25.83
12.63
10.55
27.37
Peer Median
5.23
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

--

--

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abbott Laboratories (ABT)
--
17.89
16.51
16.37
14.24
Peer Median
16.44
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.98

Higher than Peers by 0.47

Sales / Average Total Assets

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abbott Laboratories (ABT)
0.98
0.53
0.54
0.54
0.58
Peer Median
0.51
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abbott Laboratories (ABT)
--
61.20
58.73
58.20
53.15
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abbott Laboratories (ABT)
--
117.44
113.02
115.94
97.01
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abbott Laboratories (ABT)
--
78.11
75.18
80.99
77.19
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abbott Laboratories (ABT)
--
100.53
96.57
93.15
72.97
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

38.87

Lower than Peers by 8.30

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abbott Laboratories (ABT)
38.87
33.55
14.74
33.62
27.78
Peer Median
47.17
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

3.48

Lower than Peers by 0.98

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abbott Laboratories (ABT)
3.48
4.20
4.14
4.98
5.25
Peer Median
4.45
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

2.46

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abbott Laboratories (ABT)
2.46
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

21.12

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abbott Laboratories (ABT)
21.12
18.87
18.90
18.95
16.85
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

180,946

Higher than Peers by 180,347

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Abbott Laboratories (ABT)
180,946
--
--
--
--
Peer Median
599
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...

Mutual Fund Insight turns 24! 🎉 Get 2 FREE anniversary guides: The Right SIP + The Big Funds